1	Preliminary	Preliminary	B-NP	JJ	O	4	NMOD
2	X-ray	X-ray	I-NP	NN	O	4	NMOD
3	crystallographic	crystallographic	I-NP	JJ	O	4	NMOD
4	analysis	analysis	I-NP	NN	O	0	ROOT
5	of	of	B-PP	IN	O	4	NMOD
6	β-carbonic	β-carbonic	B-NP	JJ	B-protein	8	NMOD
7	anhydrase	anhydrase	I-NP	NN	I-protein	8	NMOD
8	psCA3	psCA3	I-NP	NN	I-protein	5	PMOD
9	from	from	B-PP	IN	O	8	NMOD
10	Pseudomonas	Pseudomonas	B-NP	NNP	O	11	NMOD
11	aeruginosa	aeruginosa	I-NP	NN	O	9	PMOD
12	.	.	O	.	O	4	P

1	Pseudomonas	Pseudomonas	B-NP	NN	O	2	NMOD
2	aeruginosa	aeruginosa	I-NP	NN	O	3	SUB
3	is	be	B-VP	VBZ	O	0	ROOT
4	a	a	B-NP	DT	O	6	NMOD
5	Gram-negative	Gram-negative	I-NP	JJ	O	6	NMOD
6	bacterium	bacterium	I-NP	NN	O	3	PRD
7	that	that	B-NP	WDT	O	6	NMOD
8	causes	cause	B-VP	VBZ	O	7	SBAR
9	life-threatening	life-threatening	B-NP	JJ	O	10	NMOD
10	infections	infection	I-NP	NNS	O	8	OBJ
11	in	in	B-PP	IN	O	10	NMOD
12	susceptible	susceptible	B-NP	JJ	O	13	NMOD
13	individuals	individual	I-NP	NNS	O	11	PMOD
14	and	and	O	CC	O	8	VMOD
15	is	be	B-VP	VBZ	O	8	VMOD
16	resistant	resistant	B-ADJP	JJ	O	15	PRD
17	to	to	B-PP	TO	O	16	AMOD
18	most	most	B-ADVP	RBS	O	19	AMOD
19	clinically	clinically	I-ADVP	RB	O	17	PMOD
20	available	available	B-NP	JJ	O	19	AMOD
21	antimicrobials	antimicrobial	I-NP	NNS	O	19	NMOD
22	.	.	O	.	O	3	P

1	Genomic	Genomic	B-NP	JJ	O	4	NMOD
2	and	and	I-NP	CC	O	4	NMOD
3	proteomic	proteomic	I-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	5	SUB
5	have	have	B-VP	VBP	O	0	ROOT
6	identified	identify	I-VP	VBN	O	5	VC
7	three	three	B-NP	CD	O	8	NMOD
8	genes	gene	I-NP	NNS	O	14	NMOD
9	,	,	I-NP	,	O	14	P
10	pa0102	pa0102	I-NP	NN	O	14	NMOD
11	,	,	I-NP	,	O	14	P
12	pa2053	pa2053	I-NP	NN	O	14	NMOD
13	and	and	I-NP	CC	O	14	NMOD
14	pa4676	pa4676	I-NP	NN	O	6	OBJ
15	,	,	O	,	O	14	P
16	in	in	B-PP	IN	O	14	NMOD
17	P.	P.	B-NP	NNP	O	19	NMOD
18	aeruginosa	aeruginosa	I-NP	NNP	O	19	NMOD
19	PAO1	PAO1	I-NP	NN	B-protein	16	PMOD
20	encoding	encode	B-VP	VBG	O	19	NMOD
21	three	three	B-NP	CD	O	20	OBJ
22	functional	functional	I-NP	JJ	O	24	NMOD
23	β-carbonic	β-carbonic	I-NP	JJ	B-protein	24	NMOD
24	anhydrases	anhydras	I-NP	NNS	I-protein	21	NMOD
25	(	(	O	(	O	27	DEP
26	β-CAs	β-CA	B-NP	NNS	O	27	DEP
27	)	)	O	)	O	21	NMOD
28	:	:	O	:	O	5	P
29	psCA1	psCA1	B-NP	NN	B-protein	33	NMOD
30	,	,	I-NP	,	O	33	P
31	psCA2	psCA2	I-NP	NN	B-protein	33	NMOD
32	and	and	I-NP	CC	O	33	NMOD
33	psCA3	psCA3	I-NP	NN	B-protein	5	OBJ
34	,	,	O	,	O	33	P
35	respectively	respectively	B-ADVP	RB	O	33	NMOD
36	.	.	O	.	O	5	P

1	These	These	B-NP	DT	O	2	NMOD
2	β-CAs	β-CA	I-NP	NNS	B-protein	3	SUB
3	could	could	B-VP	MD	O	0	ROOT
4	serve	serve	I-VP	VB	O	3	VC
5	as	as	B-PP	IN	O	4	VMOD
6	novel	novel	B-NP	JJ	O	9	NMOD
7	antimicrobial	antimicrobial	I-NP	JJ	O	9	NMOD
8	drug	drug	I-NP	NN	O	9	NMOD
9	targets	target	I-NP	NNS	O	5	PMOD
10	for	for	B-PP	IN	O	9	NMOD
11	this	this	B-NP	DT	O	12	NMOD
12	pathogen	pathogen	I-NP	NN	O	10	PMOD
13	.	.	O	.	O	3	P

1	X-ray	X-ray	B-NP	NN	O	4	NMOD
2	crystallographic	crystallographic	I-NP	JJ	O	4	NMOD
3	structural	structural	I-NP	JJ	O	4	NMOD
4	studies	study	I-NP	NNS	O	5	SUB
5	have	have	B-VP	VBP	O	0	ROOT
6	been	be	I-VP	VBN	O	5	VC
7	initiated	initiate	I-VP	VBN	O	6	VC
8	to	to	I-VP	TO	O	9	VMOD
9	characterize	characterize	I-VP	VB	O	7	VMOD
10	the	the	B-NP	DT	O	13	NMOD
11	structure	structure	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	function	function	I-NP	NN	O	9	OBJ
14	of	of	B-PP	IN	O	13	NMOD
15	these	these	B-NP	DT	O	16	NMOD
16	proteins	protein	I-NP	NNS	O	14	PMOD
17	.	.	O	.	O	5	P

1	This	This	B-NP	DT	O	2	NMOD
2	communication	communication	I-NP	NN	O	3	SUB
3	describes	describe	B-VP	VBZ	O	0	ROOT
4	the	the	B-NP	DT	O	5	NMOD
5	production	production	I-NP	NN	O	3	OBJ
6	of	of	B-PP	IN	O	5	NMOD
7	two	two	B-NP	CD	O	9	NMOD
8	crystal	crystal	I-NP	JJ	O	9	NMOD
9	forms	form	I-NP	NNS	O	6	PMOD
10	(	(	O	(	O	14	DEP
11	A	A	B-NP	NN	O	13	NMOD
12	and	and	O	CC	O	13	NMOD
13	B	B	B-NP	NN	O	14	DEP
14	)	)	O	)	O	9	NMOD
15	of	of	B-PP	IN	O	9	NMOD
16	β-CA	β-CA	B-NP	NN	B-protein	17	NMOD
17	psCA3	psCA3	I-NP	NN	I-protein	15	PMOD
18	.	.	O	.	O	3	P

1	Form	Form	B-NP	NN	O	2	NMOD
2	A	A	I-NP	NN	O	12	SUB
3	diffracted	diffract	B-VP	VBN	O	2	NMOD
4	to	to	B-PP	TO	O	3	VMOD
5	a	a	B-NP	DT	O	6	NMOD
6	resolution	resolution	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	2.9	2.9	B-NP	CD	O	9	NMOD
9	Å	Å	I-NP	NN	O	7	PMOD
10	;	;	O	:	O	12	P
11	it	it	B-NP	PRP	O	12	SUB
12	belonged	belong	B-VP	VBD	O	0	ROOT
13	to	to	I-VP	TO	O	14	VMOD
14	space	space	I-VP	VB	O	12	VMOD
15	group	group	B-NP	NN	O	16	NMOD
16	P212121	P212121	I-NP	NN	O	14	OBJ
17	,	,	O	,	O	14	P
18	with	with	B-PP	IN	O	14	VMOD
19	unit-cell	unit-cell	B-NP	NN	O	20	NMOD
20	parameters	parameter	I-NP	NNS	O	18	PMOD
21	a	a	B-NP	DT	O	32	NMOD
22	=	=	I-NP	JJ	O	32	NMOD
23	81.9	81.9	I-NP	CD	O	22	AMOD
24	,	,	O	,	O	32	P
25	b	b	B-NP	NN	B-protein	32	NMOD
26	=	=	B-VP	SYM	I-protein	25	NMOD
27	84.9	84.9	B-NP	CD	I-protein	26	AMOD
28	,	,	O	,	O	32	P
29	c	c	B-NP	NN	O	32	SUB
30	=	=	B-VP	SYM	O	32	VMOD
31	124.2	124.2	B-NP	CD	O	32	NMOD
32	Å	Å	I-NP	NN	O	14	OBJ
33	,	,	O	,	O	12	P
34	and	and	O	CC	O	12	VMOD
35	had	have	B-VP	VBD	O	12	VMOD
36	a	a	B-NP	DT	O	39	NMOD
37	calculated	calculate	I-NP	VBN	O	39	NMOD
38	Matthews	Matthews	I-NP	NNP	O	39	NMOD
39	coefficient	coefficient	I-NP	NN	O	35	OBJ
40	of	of	B-PP	IN	O	39	NMOD
41	2.23	2.23	B-NP	CD	B-protein	46	NMOD
42	Å³	Å³	I-NP	NNP	I-protein	43	NMOD
43	Da⁻¹	Da⁻¹	I-NP	NNP	I-protein	46	NMOD
44	assuming	assume	B-VP	VBG	I-protein	46	NMOD
45	four	four	B-NP	CD	I-protein	46	NMOD
46	molecules	molecule	I-NP	NNS	I-protein	40	PMOD
47	in	in	B-PP	IN	O	35	VMOD
48	the	the	B-NP	DT	O	51	NMOD
49	crystallographic	crystallographic	I-NP	JJ	O	51	NMOD
50	asymmetric	asymmetric	I-NP	JJ	O	51	NMOD
51	unit	unit	I-NP	NN	O	47	PMOD
52	.	.	O	.	O	12	P

1	Form	Form	B-NP	NN	O	2	NMOD
2	B	B	I-NP	NN	O	3	SUB
3	diffracted	diffract	B-VP	VBD	O	12	VMOD
4	to	to	B-PP	TO	O	3	VMOD
5	a	a	B-NP	DT	O	6	NMOD
6	resolution	resolution	I-NP	NN	O	4	PMOD
7	of	of	B-PP	IN	O	6	NMOD
8	3.0	3.0	B-NP	CD	O	9	NMOD
9	Å	Å	I-NP	NN	O	7	PMOD
10	;	;	O	:	O	12	P
11	it	it	B-NP	PRP	O	12	SUB
12	belonged	belong	B-VP	VBD	O	0	ROOT
13	to	to	I-VP	TO	O	14	VMOD
14	space	space	I-VP	VB	O	12	VMOD
15	group	group	B-NP	NN	O	16	NMOD
16	P21212	P21212	I-NP	NN	O	14	OBJ
17	,	,	O	,	O	14	P
18	with	with	B-PP	IN	O	14	VMOD
19	unit-cell	unit-cell	B-NP	NN	O	20	NMOD
20	parameters	parameter	I-NP	NNS	O	18	PMOD
21	a	a	B-NP	DT	O	32	NMOD
22	=	=	I-NP	JJ	O	32	NMOD
23	69.9	69.9	I-NP	CD	O	22	AMOD
24	,	,	O	,	O	32	P
25	b	b	B-NP	NN	B-protein	32	NMOD
26	=	=	B-VP	SYM	I-protein	25	NMOD
27	77.7	77.7	B-NP	CD	I-protein	26	AMOD
28	,	,	O	,	O	32	P
29	c	c	B-NP	NN	B-protein	32	NMOD
30	=	=	B-VP	SYM	I-protein	32	NMOD
31	88.5	88.5	B-NP	CD	I-protein	32	NMOD
32	Å	Å	I-NP	NN	I-protein	14	OBJ
33	,	,	O	,	O	12	P
34	and	and	O	CC	O	12	VMOD
35	had	have	B-VP	VBD	O	12	VMOD
36	a	a	B-NP	DT	O	39	NMOD
37	calculated	calculate	I-NP	VBN	O	39	NMOD
38	Matthews	Matthews	I-NP	NNP	O	39	NMOD
39	coefficient	coefficient	I-NP	NN	O	35	OBJ
40	of	of	B-PP	IN	O	39	NMOD
41	2.48	2.48	B-NP	CD	O	43	NMOD
42	Å³	Å³	I-NP	NNP	O	43	NMOD
43	Da⁻¹	Da⁻¹	I-NP	NNP	O	40	PMOD
44	assuming	assume	B-VP	VBG	O	43	NMOD
45	two	two	B-NP	CD	O	46	NMOD
46	molecules	molecule	I-NP	NNS	O	44	OBJ
47	in	in	B-PP	IN	O	44	VMOD
48	the	the	B-NP	DT	O	51	NMOD
49	crystallographic	crystallographic	I-NP	JJ	O	51	NMOD
50	asymmetric	asymmetric	I-NP	JJ	O	51	NMOD
51	unit	unit	I-NP	NN	O	47	PMOD
52	.	.	O	.	O	12	P

1	Preliminary	Preliminary	B-NP	JJ	O	3	NMOD
2	molecular-replacement	molecular-replacement	I-NP	NN	O	3	NMOD
3	solutions	solution	I-NP	NNS	O	4	SUB
4	have	have	B-VP	VBP	O	0	ROOT
5	been	be	I-VP	VBN	O	4	VC
6	determined	determine	I-VP	VBN	O	5	VC
7	with	with	B-PP	IN	O	6	VMOD
8	the	the	B-NP	DT	O	13	NMOD
9	PHENIX	PHENIX	I-NP	NN	O	11	NMOD
10	AutoMR	AutoMR	I-NP	NN	O	11	NMOD
11	wizard	wizard	I-NP	NN	O	13	NMOD
12	and	and	I-NP	CC	O	13	NMOD
13	refinement	refinement	I-NP	NN	O	7	PMOD
14	of	of	B-PP	IN	O	13	NMOD
15	both	both	B-NP	DT	O	17	NMOD
16	crystal	crystal	I-NP	JJ	O	17	NMOD
17	forms	form	I-NP	NNS	O	14	PMOD
18	is	be	B-VP	VBZ	O	4	VMOD
19	currently	currently	B-ADVP	RB	O	18	VMOD
20	in	in	B-PP	IN	O	18	VMOD
21	progress	progress	B-NP	NN	O	20	PMOD
22	.	.	O	.	O	4	P

